

5 FACTS YOU DON'T KNOW ABOUT LUNG CANCER

Lung cancer is the second most commonly diagnosed cancer in both men and women in the United States and the leading cause of all cancer deaths.¹

1

IT'S NOT JUST ONE DISEASE

Lung cancer is divided into 2 major types¹



Small Cell Lung Cancer
accounts for about
1 out of 10 cases



Non-Small Cell Lung Cancer
accounts for almost
9 out of 10 cases

2

MANY PEOPLE AREN'T TREATED

Many Americans diagnosed with advanced cancer never receive cancer care

68% of these people have lung cancer²



3

THOSE WHO DO GET TREATED MAY NOW HAVE MORE OPTIONS

WE BETTER UNDERSTAND HOW TUMORS GROW AND SURVIVE

Genetic discoveries specific to lung cancer have helped to personalize treatments^{3,4}



EGFR⁵
10-15%

ALK⁶
3-5%

MET⁷
50%

4

IT CAN AFFECT ANYONE



> 20,000 AMERICANS
who have never smoked are diagnosed with lung cancer each year^{1,8}



MORE WOMEN DIE OF LUNG CANCER
than of BREAST
OVARIAN
UTERINE } cancers combined⁹



MORE COMMON IN PEOPLE
> 45
years old, but genetics can put younger people at risk¹



5

EARLY DIAGNOSIS IS IMPORTANT

TALK TO
YOUR
DOCTOR



if you think
you're at risk

GET
TESTED



Genetic or protein markers can determine if a targeted treatment may be appropriate^{3,4}

KNOW THE
TREATMENT
OPTIONS

- Surgery
- Radiation therapy
- Chemotherapy
- Targeted medicines¹



REFERENCES

1. American Cancer Society. Lung Cancer (Non-Small Cell) Detailed Guide. <http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf>.
2. Small C, Tsao C, Moshier E, et al. Prevalence and Characteristics of Patients With Stage IV Solid Tumors Who Receive No Anticancer Therapy. *Journal of Clinical Oncology*. 2012;30:suppl abstr 6065.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
4. Keedy V, Termini S, Somerfield M, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. *Journal of Clinical Oncology*. 2011;29(15):2121-2127.
5. Socinski M. The Emerging Role of Biomarkers in Advanced Non-Small-Cell Lung Cancer. *Clinical Lung Cancer*. 2010;11:149-159.
6. Garber K. ALK, Lung Cancer, and Personalized Therapy: Portent of the Future? *Journal of the National Cancer Institute*. 2010;102:672-675.
7. Cipriani N, Abidoye O, Vokes E, Salgia R. MET as a Target for Treatment of Chest Tumors. *Lung Cancer*. 2009;63(2):169-179.
8. Subramanian J, Govindan R. Lung Cancer in Never Smokers: A Review. *Journal of Clinical Oncology*. 2007;25:561-570.
9. American Cancer Society. Facts & Figures 2013. <http://www.cancer.org/acs/groups/content/epidemiologysurveillance/documents/document/acspc-036845.pdf>.